Co-inhibition of adenosine generation and signalling: a new combination cancer therapy [ 2017 - 2019 ]

Research Grant

Researchers: A/Pr Michele Teng (Principal investigator) ,  Prof Mark Smyth (Principal investigator)

Brief description Cancer is a major killer of Australians and there is a need to develop new combination therapies that halt cancer growth and spread. A metabolic product of the cancer called adenosine can be exploited by several different treatment approaches. Surprisingly we have found that both preventing adenosine generation and its effects on immune cells can together more effectively slow tumour growth and spread. If we can better understand why, this approach can be quickly brought it to clinical practice.

Funding Amount $AUD 601,697.81

Funding Scheme Project Grants

Notes Standard Project Grant